AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03209219
Drug: Cyclosporine Pill
RxNorm normalized name: cyclosporine Pill
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg， oral, bid
Trial: NCT03336502
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 18 mg/mL IV solution; posaconazole 40 mg/mL oral suspension
Trial: NCT01438034
Drug: kisspeptin 112-121
RxNorm normalized name: Kisspeptin
DrugBank: Kisspeptin (DB19112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.24 nmol/kg
Trial: NCT01438034
Drug: GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 ng/kg
Trial: NCT00139165
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capsule. Oral 6 mg o.d. for 24 weeks
Trial: NCT00915681
Drug: Silibinin
RxNorm normalized name: Silibinin
DrugBank: Silibinin (DB09298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg continuous IV is over 24 hours
Trial: NCT03530371
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients
Trial: NCT04775329
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 1000mg OM
Trial: NCT02797808
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Impact of sertraline on functional brain connectivity
Trial: NCT00466401
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02437747
Drug: SRP + Aloe
RxNorm normalized name: Aloe
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing along with aloe vera application was done
Trial: NCT02261727
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone is an oral glucocorticosteroid which has anti-inflammatory properties
Trial: NCT02636088
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00083083
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00083083
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00083083
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00083083
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00083083
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00083083
Drug: vinblastine sulfate
RxNorm normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00083083
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02057315
Drug: ELS-M11
RxNorm normalized name: HYDROXYPROPYL CELLULOSE (TYPE EL)
DrugBank: Hydroxypropyl cellulose (DB00840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of 5% ELS-M11 over 3 bilateral applications.
Trial: NCT00207688
Drug: Infliximab 5 mg/kg
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
Trial: NCT00207688
Drug: Infliximab 10 mg/kg
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
Trial: NCT00857727
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine will be dissolved in saline. An initial loading dose of 1.0 mg/kg given over 10 minutes followed by a continuous infusion at 0.4-0.7 mg/kg/hour. Beginning approximately one hour prior to end of surgery and continuing for one hour of recovery in the PACU and the PICU. This, the maximum dose for any one patient will be 2.4 mg/kg
Trial: NCT00857727
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by a continuous infusion
Trial: NCT00813423
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00813423
Drug: Sunitinib Malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01445028
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin 20mg daily for 12 weeks
Trial: NCT01803360
Drug: Neridronate
RxNorm normalized name: Neridronate
DrugBank: Neridronic Acid (DB11620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
Trial: NCT03934450
Drug: RPQ
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
Trial: NCT03934450
Drug: SPQ
RxNorm normalized name: Sulfapyridine
DrugBank: Sulfapyridine (DB00891)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
Trial: NCT03934450
Drug: Primaquine Phosphate
RxNorm normalized name: Primaquine Phosphate
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
Trial: NCT00211146
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02705638
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
Trial: NCT02705638
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
Trial: NCT01388738
Drug: citicoline
RxNorm normalized name: Citicoline
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: citicoline IV 2000 mg, then citicoline 900 mg/day (300mg\*3 times per day) per os
Trial: NCT01936545
Drug: propofol during liver transplantation.
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The anesthesia was maintained with propofol during liver transplantation.
Trial: NCT01936545
Drug: Desflurane during liver transplantation.
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The anesthesia was maintained with desflurane during liver transplantation.
Trial: NCT01084265
Drug: Recombinant human luteinizing hormone (r-hLH)
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One r-hLH (75 International Units \[IU\]) injection s.c. once daily.
Trial: NCT01084265
Drug: Recombinant human follicle-stimulating hormone (r-hFSH)
RxNorm normalized name: Recombinant human follicle-stimulating hormone (r-HFSH)
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One r-hFSH (150 IU) injection s.c. once daily.
Trial: NCT01084265
Drug: Human chorionic gonadotropin (hCG)
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG.
Trial: NCT00153842
Drug: Bexarotene (targretin)
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).~Level 1: 300 mg
Trial: NCT00153842
Drug: Bexarotene (targretin)
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bexarotene oral capsules will be administered daily beginning on the intitial day of chemotherapy (Day 1).~Level 2: 400 mg
Trial: NCT00513032
Drug: methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
Trial: NCT01388738
Drug: cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin IV 10 ml daily 10 days
Trial: NCT00437307
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
Trial: NCT02429440
Drug: Montanide ISA-51
RxNorm normalized name: isopropyl alcohol
DrugBank: Incomplete Freund's adjuvant (DB17475)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous
Trial: NCT00386178
Drug: Vitamin E supplement rich in gamma tocopherol
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily dose of Vitamin E supplement rich in gamma tocopherol
Trial: NCT00016887
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04150887
Drug: Cusatuzumab
RxNorm normalized name: Cusatuzumab
DrugBank: Cusatuzumab (DB15100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cusatuzumab will be administered as a dose of 10mg/kg or 20mg/kg intravenously.
Trial: NCT04150887
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine will be administered 75 mg/m\^2 subcutaneously or intravenously.
Trial: NCT04150887
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
Trial: NCT00016887
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00016887
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00016887
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00016887
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02972255
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem will be administered as per schedule described in individual arm.
Trial: NCT01098071
Drug: mometasone furoate nasal spray
RxNorm normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months
Trial: NCT03324997
Drug: Restylane Silk
RxNorm normalized name: SILK
DrugBank: Bombyx mori fiber (DB10609)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restylane Silk is a temporary hyaluronic acid filler currently approved for the lips and fine lines around the mouth.
Trial: NCT03324997
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline as placebo
Trial: NCT01312844
Drug: Scopolamine
RxNorm normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
Trial: NCT03401528
Drug: AVB-S6-500
RxNorm normalized name: AVB-S6-500
DrugBank: Batiraxcept (DB17522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVB-S6-500 is an investigational drug.
Trial: NCT02750163
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol will be given to febrile septic patients
Trial: NCT01595152
Drug: solifenacin succinate
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg once daily for 60 days
Trial: NCT01595152
Drug: fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg, once daily for 60 dyas
Trial: NCT03665402
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One of the first line anti-tubercolosis drug
Trial: NCT02037737
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02776488
Drug: Sodium Lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion of exogenous sodium lactate
Trial: NCT00006366
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03089073
Drug: Desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60μg or 120μg once daily at bedtime
Trial: NCT02601573
Drug: Grazoprevir
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.
Trial: NCT02601573
Drug: Elbasvir
RxNorm normalized name: Elbasvir
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.
Trial: NCT02601573
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).
Trial: NCT02601573
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SOF 400 mg tablet taken q.d. by mouth in the morning with food.
Trial: NCT02244242
Drug: Tamsulosin hydrochloride
RxNorm normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00909311
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: capsule, QD, 1 dose in each cross-over period
Trial: NCT04380181
Drug: dobu
RxNorm normalized name: Dobutrex
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of dobutamine versus milrinone and epinephrine for separation from cardiopulmonary bypass
Trial: NCT00835263
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg Tablet
Trial: NCT00709254
Drug: 3 mL AeroLEF (500 µg/1 mL)
RxNorm normalized name: AeroLEF
DrugBank: AeroLEF (DB05000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
Trial: NCT00709254
Drug: 3 mL AeroLEF (500 µg/1 mL)
RxNorm normalized name: AeroLEF
DrugBank: AeroLEF (DB05000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
Trial: NCT03011476
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Start with 5 mg/day for 4 weeks~2. Increased to 10 mg/day for 8 weeks
Trial: NCT04004884
Drug: Ulipristal Acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Assess the variations of liver blood test parameters during UPA treatment for symptomatic uterine fibroids
Trial: NCT00927771
Drug: azelaic acid gel
RxNorm normalized name: AZELAIC ACID 0.15 g in 1 g TOPICAL GEL [Azelaic Acid Gel]
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: azelaic acid 15% gel twice a day for 6 months
Trial: NCT00927771
Drug: hydroquinone cream
RxNorm normalized name: Hydroquinone Cream
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydroquinone 4% cream twice a day for 6 months
Trial: NCT03127371
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
Trial: NCT03127371
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
Trial: NCT01399580
Drug: Atrasentan
RxNorm normalized name: ATRASENTAN
DrugBank: Atrasentan (DB06199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.
Trial: NCT01895322
Drug: OPC-41061
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01121393
Drug: Gemcitabine+Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine d1,8, Cisplatin d1, 21 days as a course, up to 6 courses.
Trial: NCT01839344
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg tablet; oral single dose of 100 mg
Trial: NCT00003035
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00003035
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03366584
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 6 mg
Trial: NCT04192344
Drug: ABSK021
DrugBank: BSK02 (DB17434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABSK021 oral capsule
Trial: NCT02925130
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.
Trial: NCT01384578
Drug: pentoxiphylline and Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
Trial: NCT01384578
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in control group will receive vitamin E 800 IU/day
Trial: NCT03177083
Drug: peginterferon beta-1a
RxNorm normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SC every 2 weeks
Trial: NCT03217825
Drug: Rostafuroxin
RxNorm normalized name: Rostafuroxin
DrugBank: Rostafuroxin (DB12350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model.
Trial: NCT03217825
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-\[p-(o-1H-tetrazol-5-ylphenyl)benzyl\]imidazole- 5-methanol monopotassium salt.
Trial: NCT03177083
Drug: interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Per Summary of Product Characteristics (SMPC)